GLP-1 users warned of six rebound risks after stopping drugs
Summarised from 2 outlets · Updated 12 Nov, 21:27 · Archive
Users of GLP-1 weight-loss and diabetes medications face potential rebound effects after stopping them, a physician warns.
Users of GLP-1 medications including Ozempic, Wegovy and Zepbound face six potential rebound risks after stopping the drugs, according to Dr Frank Dumont, an internal medicine physician and executive medical director at Virta Health in San Francisco. Research has found that stopping these medications can bring rapid weight regain and loss of cardiovascular protection, among other complications.
Dumont noted that patients stop taking GLP-1 medications for various reasons. Some cite medical concerns or side effects, while others prefer not to remain on long-term medication. Common side effects include nausea, vomiting, constipation and diarrhoea. Dumont told Fox News Digital that these effects 'can become troublesome enough that people actually have a hard time eating enough food to get good nourishment'. He emphasised the importance of working with physicians to decide whether to continue or stop the medicine.
More serious side effects, such as acute pancreatitis, warrant immediate discontinuation of the drug. 'We know that's fairly rare, but if the pancreas becomes involved, that is not a good thing,' Dumont said. 'It can be very serious. It can even be life-threatening.' Certain GLP-1 medications carry a warning about thyroid tumours based on animal studies, though the risk in humans remains unknown. These medications should not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

How it is being reported
- GLP-1 users face 6 rebound risks after stopping the weight-loss drugsWhile GLP-1 medications like Ozempic, Wegovy and Zepbound have reshaped weight management and diabetes control, research shows that many patients stop taking them within a year.New York Post · 12 Nov, 21:17
- Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warnsThinking of quitting a GLP-1? A physician outlines six risks, from weight regain and muscle loss to worsening biomarkers and mental health consequences.Fox News · 12 Nov, 13:00
In this story: Ozempic · Wegovy · Zepbound · Dr Frank Dumont · Virta Health · San Francisco
This summary was written by AI from the headlines and standfirsts above, and states as fact only what at least two outlets report. How we use AI · Report a problem · Corrections log
Comments (0)